HealthCare Global Enterprises Limited (HCG.NS)
- Previous Close
595.65 - Open
601.90 - Bid --
- Ask --
- Day's Range
573.00 - 601.90 - 52 Week Range
330.65 - 601.95 - Volume
300,374 - Avg. Volume
304,826 - Market Cap (intraday)
80.233B - Beta (5Y Monthly) -0.07
- PE Ratio (TTM)
140.02 - EPS (TTM)
4.11 - Earnings Date May 27, 2025 - May 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
537.43
HealthCare Global Enterprises Limited, together with its subsidiaries, provides medical and healthcare services focusing on cancer and fertility in India and internationally. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, including reproductive medicine, assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates multi-specialty hospitals under the HCG brand that provides inpatient and outpatients treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care. In addition, the company offers cancer diagnostic services; combining laboratory services; and research and development, and clinical research to enhance cancer diagnosis and prognosis. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.
www.hcgoncology.com6,150
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: HCG.NS
View More
Performance Overview: HCG.NS
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HCG.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HCG.NS
View MoreValuation Measures
Market Cap
83.04B
Enterprise Value
95.66B
Trailing P/E
144.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.96
Price/Book (mrq)
9.64
Enterprise Value/Revenue
4.53
Enterprise Value/EBITDA
23.99
Financial Highlights
Profitability and Income Statement
Profit Margin
2.73%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
21.32B
Net Income Avi to Common (ttm)
583.25M
Diluted EPS (ttm)
4.11
Balance Sheet and Cash Flow
Total Cash (mrq)
2.9B
Total Debt/Equity (mrq)
172.04%
Levered Free Cash Flow (ttm)
--